Title:
Ｂ型肝炎抗ウイルス剤
Document Type and Number:
Japanese Patent JP6904970
Kind Code:
B2
Abstract:
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:X-A-Y-L-R (I)which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
More Like This:
Inventors:
Ju, Yao-Lin
Gao, Sri
Re, way
Khao, Hui
Gin, majion
Kas, Jordan
Pen, Xiaowen
Oru, Yat, Sun
Gao, Sri
Re, way
Khao, Hui
Gin, majion
Kas, Jordan
Pen, Xiaowen
Oru, Yat, Sun
Application Number:
JP2018547442A
Publication Date:
July 21, 2021
Filing Date:
March 06, 2017
Export Citation:
Assignee:
Enanta Pharmaceuticals, Inc.
International Classes:
C07C317/44; A61K31/167; A61K31/336; A61K31/341; A61K31/35; A61K31/351; A61K31/357; A61K31/365; A61K31/39; A61K31/401; A61K31/41; A61K31/415; A61K31/4164; A61K31/42; A61K31/421; A61K31/426; A61K31/439; A61K31/44; A61K31/4402; A61K31/4406; A61K31/4409; A61K31/4425; A61K31/4439; A61K31/444; A61K31/4453; A61K31/5375; A61K45/00; A61P31/20; A61P43/00; C07C317/48; C07D207/16; C07D207/46; C07D211/00; C07D211/54; C07D213/30; C07D213/32; C07D213/55; C07D213/61; C07D213/62; C07D213/71; C07D213/74; C07D213/75; C07D213/89; C07D231/12; C07D233/20; C07D233/22; C07D257/04; C07D261/08; C07D261/10; C07D263/38; C07D277/26; C07D295/088; C07D303/22; C07D303/34; C07D307/12; C07D307/20; C07D307/58; C07D309/04; C07D309/06; C07D309/08; C07D313/04; C07D317/36; C07D317/72; C07D327/10; C07D401/04; C07D487/08; C07D493/08; C07F7/10
Domestic Patent References:
| JP2012526820A | ||||
| JP2010526151A | ||||
| JP2013507350A | ||||
| JP2015531773A | ||||
| JP2015533782A | ||||
| JP2016509591A | ||||
| JP2015506927A | ||||
| JP2014523901A |
Foreign References:
| WO2016089990A1 | ||||
| DE10109856A1 | ||||
| WO2013163404A1 | ||||
| WO2009131065A1 | ||||
| WO2010123139A1 | ||||
| WO2015109130A1 | ||||
| WO2004018414A2 |
Other References:
Flachner, Beata; Toemoeri, Tuende; Hajdu, Istvan; Dobi, Krisztina; Lorincz, Zsolt; Cseh, Sandor; Dorman, Gyoergy,Rapid in silico selection of an MCHR1 antagonists' focused library from multi-million compounds' repositories: biological evaluation,Medicinal Chemistry Research ,2014年,23(3),,1234-1247
Stachulski, Andrew V.; Pidathala, Chandrakala; Row, Eleanor C.; Sharma, Raman; Berry, Neil G.; Iqbal, Mazhar; Bentley, Joanne; Allman, Sarah A.; Edwards, Geoffrey; Helm, Alison; Hellier, Jennifer; Korba, Brent E.; Semple, J. Edward; Rossignol, Jean-Francois,Thiazolides as Novel Antiviral Agents. 1. Inhibition of Hepatitis B Virus Replication,Journal of Medicinal Chemistry ,2011年,54(12),,4119-4132
Stachulski, Andrew V.; Pidathala, Chandrakala; Row, Eleanor C.; Sharma, Raman; Berry, Neil G.; Iqbal, Mazhar; Bentley, Joanne; Allman, Sarah A.; Edwards, Geoffrey; Helm, Alison; Hellier, Jennifer; Korba, Brent E.; Semple, J. Edward; Rossignol, Jean-Francois,Thiazolides as Novel Antiviral Agents. 1. Inhibition of Hepatitis B Virus Replication,Journal of Medicinal Chemistry ,2011年,54(12),,4119-4132
Attorney, Agent or Firm:
Asamura patent office